The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.
|Videos|July 2, 2021
Safety Profile of Dapagliflozin Among Patients With Type 2 Diabetes Hospitalized With COVID-19
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod addressed the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
Advertisement
Related to this article
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
4
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
5